Financial instruments - Collaboration and License Agreement (Details) |
12 Months Ended |
---|---|
Dec. 31, 2020
USD ($)
customer
| |
Collaboration and License Agreement | |
Number of customers | customer | 2 |
Trade receivables | $ 139,000 |
Amounts past due | 0 |
GlaxoSmithKline Intellectual Property Development Ltd | Astellas Collaboration Agreement | |
Collaboration and License Agreement | |
Impairment losses | $ 0 |
X | ||||||||||
- Definition Number of customers. No definition available.
|
X | ||||||||||
- Definition Amounts past due. No definition available.
|
X | ||||||||||
- Definition Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Definition Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|